CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570) Cancer Therapeutics (1180)
Abgenix aims to deliver fully human monoclonal antibodies for a range of disease targets, several of which are currently in clinical trials. The company leverages its XenoMouse technology platform to support product development, while offering the pl...Show all
Company (Acquired)
Phone: 510-284-6500
6701 Kaiser Drive
Fremont, 94555
California, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Abgenix | $246.6M | Apr 1, 2006 |
| Ribozyme Pharmaceuticals | $0M | Oct 26, 2019 |
| ApoLife | $0M | Oct 26, 2019 |
| See all 15 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Method for preparing monoclonal antibody | Sep 28, 2005 | Aug 07, 2012 | Patent |
| Antibodies to cd40 and methods of treating cancer and enhancing immune responses | Aug 26, 2005 | Jul 21, 2009 | Patent |
